Innoviva, Inc. (INVA) vs Maze Therapeutics, Inc. (MAZE)

A side-by-side comparison of Innoviva, Inc. and Maze Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — INVA vs MAZE

growth of $100 · dividends reinvested · last 2y
INVA +9.3% (+4.5%/yr)MAZE +65.7% (+28.7%/yr)MAZE compounded faster over this window
100200300Start $1002026$109$166
INVA MAZE

INVA vs MAZE: by the numbers

  • •INVA is the larger company ($1.54B vs $1.46B market cap).
  • •INVA is profitable (80.56% net margin) while MAZE runs a net loss (-667.95%).

Metrics side by side

Valuation

MetricINVAMAZE
P/E ratio5.09N/A
Forward P/E8.62N/A
PEG ratio0.49N/A
P/S ratio3.4773.25
P/B ratio1.253.23
EV / EBITDA4.91N/A
FCF yield12.23%N/A

Profitability

MetricINVAMAZE
Gross margin73.09%0.00%
Operating margin36.66%0.00%
Net margin80.56%-667.95%
ROE28.97%-29.48%
ROIC8.36%-28.63%

Growth (annualized)

MetricINVAMAZE
Revenue CAGR (5Y)3.94%N/A
EPS CAGR (5Y)12.71%N/A
FCF CAGR (5Y)-10.54%N/A
Total return CAGR (5Y)4.52%N/A

Frequently asked

Is INVA or MAZE more profitable?
INVA runs the higher net margin — INVA at 80.56% versus MAZE at -667.95%.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.